What's new? Log in Free sign up

Repligen (RGEN) News and press releases

Company Profile

News

From Benzinga Pro

SVB Leerink Maintains Outperform on Repligen, Lowers Price Target to $200

News, Price Target, Analyst Ratings

SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and lowers the price target from $230 to $200.

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Deutsche Bank Initiates Coverage On Repligen with Hold Rating, Announces Price Target of $180

News, Price Target, Initiation, Analyst Ratings

Deutsche Bank analyst Justin Bowers initiates coverage on Repligen (NASDAQ:RGEN) with a Hold rating and announces Price Target of $180.

Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock

Analyst Color, News, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General

RBC Capital Initiates Coverage On Repligen with Sector Perform Rating, Announces Price Target of $190

News, Price Target, Initiation, Analyst Ratings

RBC Capital analyst Conor McNamara initiates coverage on Repligen (NASDAQ:RGEN) with a Sector Perform rating and announces Price Target of $190.

Repligen Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) posted Q3 earnings of $40.41 million, an increase from Q2 of 18.96%. Sales dropped to $200.74 million, a 3.32% decrease between quarters.

Recap: Repligen Q3 Earnings

Repligen (NASDAQ:RGEN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Repligen beat estimated earnings by 13.24%, reporting an EPS of $0.77 versus an estimate of $0.68.

Repligen Q3 EPS $0.77 Beats $0.68 Estimate, Sales $200.71M Beat $192.39M Estimate

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.68 by 13.24 percent. This is a 1.28 percent decrease over earnings of $0.78 per share from the same

Repligen Extends And Expands Long-Term Supply Agreement With Purolite For Affinity Ligands; Terms Not Disclosed

News, Contracts

Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company ("Purolite"), for the development and manufacturing of affinity

Earnings Scheduled For November 1, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Press releases

From Benzinga Pro

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

News, Press Releases

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P.

Repligen Corporation to Present at Upcoming Investor Conferences

News, Press Releases

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming

Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

Earnings, Press Releases

Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers base business growth of 29% for the quarterExpands Process

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

Health Care, Press Releases

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company ("Purolite"), for the